4.4 Article

Arterial stiffness and peripheral arterial disease in patients with systemic lupus erythematosus

Journal

RHEUMATOLOGY INTERNATIONAL
Volume 37, Issue 2, Pages 293-298

Publisher

SPRINGER HEIDELBERG
DOI: 10.1007/s00296-016-3610-4

Keywords

Systemic lupus erythematosus; Arterial stiffness; Peripheral arterial disease; Ankle brachial index; Pulse wave velocity; Augmentation index

Categories

Ask authors/readers for more resources

Systemic lupus erythematosus (SLE) is associated with increased cardiovascular risk. We aimed to evaluate arterial stiffness and the ankle brachial index (ABI), two markers of subclinical cardiovascular disease, in SLE. We studied 55 patients with SLE (12.7% males, age 53.3 +/- 15.3 years) and 61 age- and gender-matched controls. Arterial stiffness was evaluated by measuring pulse wave velocity (PWV), augmentation index (AIx) and central systolic, diastolic, pulse and mean blood pressure (BP). Peripheral arterial disease was defined as ABI <= 0.90. Regarding markers of arterial stiffness, patients with SLE had lower PWV and AIx than controls (p < 0.01 and p < 0.05, respectively). However, after adjusting for differences in cardiovascular risk factors between patients with SLE and controls, PWV and AIx did not differ between the two groups. Central systolic, diastolic, pulse and mean BP also did not differ between the two groups. In patients with SLE, PWV correlated independently with systolic BP (B = 0.05, p < 0.001) and waist/hip ratio (B = 6.72, p < 0.05). Regarding ABI, the lowest ABI was lower in patients with SLE than in controls (p < 0.005). However, after adjusting for differences in cardiovascular risk factors between patients with SLE and controls, the lowest ABI did not differ between the two groups. The prevalence of PAD also did not differ between patients with SLE and controls (10.0 and 5.4%, respectively; p = NS). Markers of arterial stiffness and the ABI do not appear to differ between patients with SLE and age- and gender-matched controls. However, given the small sample size, larger studies are needed to clarify whether SLE promotes arterial stiffness and PAD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Rheumatology

Medium Versus High Initial Prednisone Dose for Remission Induction in Lupus Nephritis: A Propensity Score-Matched Analysis

Konstantinos Tselios, Dafna D. Gladman, Haifa Al-Sheikh, Jiandong Su, Murray B. Urowitz

Summary: This study compares the complete renal response rates of lupus nephritis patients treated with low-dose (<= 30 mg/day) or high-dose (>= 40 mg/day) prednisone. The results show that high-dose prednisone achieved better rates of complete response at 12 months and higher rates of complete remission at 2 and 3 years after diagnosis. Cumulative glucocorticoid dose and damage accrual were similar in both groups.

ARTHRITIS CARE & RESEARCH (2022)

Review Gastroenterology & Hepatology

Circulating adiponectin in patients with nonalcoholic fatty liver disease-related liver fibrosis: A systematic review and a meta-analysis

Christina Tontikidou, Evangelia S. Makri, Kleo Evripidou, Dimitrios G. Goulis, Antonis Goulas, Stergios A. Polyzos

Summary: Overall, there was no significant difference in total adiponectin concentrations between NAFLD patients with and without liver fibrosis. However, after excluding specific populations and methods, it was found that adiponectin concentrations were lower in NAFLD patients with fibrosis among adult patients.

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2022)

Review Health Care Sciences & Services

Combination Therapies for Nonalcoholic Fatty Liver Disease

Evangelia S. Makri, Eleftheria Makri, Stergios A. Polyzos

Summary: Nonalcoholic fatty liver disease (NAFLD) is a prevalent disease associated with various comorbidities, leading to a socioeconomic burden. Despite the lack of approved pharmacological treatment for NAFLD, combination therapies may be a rational alternative due to the multifaceted pathophysiology of the disease.

JOURNAL OF PERSONALIZED MEDICINE (2022)

Review Health Care Sciences & Services

Cardiovascular Risk Prediction Models and Scores in the Era of Personalized Medicine

Areti Sofogianni, Nikolaos Stalikas, Christina Antza, Konstantinos Tziomalos

Summary: Cardiovascular disease is the leading cause of death worldwide, and managing cardiovascular risk factors such as hypertension and dyslipidemia is crucial for reducing cardiovascular morbidity and mortality. However, there is currently no definitive optimal cardiovascular risk prediction equation, so country-specific risk scores should be preferred for cardiovascular risk stratification.

JOURNAL OF PERSONALIZED MEDICINE (2022)

Review Health Care Sciences & Services

The Role of Angiotensin Receptor Blockers in the Personalized Management of Diabetic Neuropathy

Danai-Thomais Kostourou, Dimitrios Milonas, Georgios Polychronopoulos, Areti Sofogianni, Konstantinos Tziomalos

Summary: This article discusses the role and mechanisms of angiotensin receptor blockers (ARBs) in the prevention of diabetic neuropathy. The findings suggest that ARBs may be helpful in delaying and preventing the progression of diabetic neuropathy, but further research is needed to clarify their role in the management of this complication of diabetes.

JOURNAL OF PERSONALIZED MEDICINE (2022)

Article Health Care Sciences & Services

Evaluation of Subclinical Vascular Disease in Diabetic Kidney Disease: A Tool for Personalization of Management of a High-Risk Population

Christodoula Kourtidou, Vasileios Rafailidis, Garyfallia Varouktsi, Efthimios Kanakis, Vassilios Liakopoulos, Timoleon-Achilleas Vyzantiadis, Maria Stangou, Smaragdi Marinaki, Konstantinos Tziomalos

Summary: Patients with diabetic kidney disease (DKD) have a higher risk of cardiovascular events, which may be related to subclinical vascular disease that is not fully explained by traditional risk factors. Evaluating the presence of subclinical vascular disease could improve risk stratification and management of these patients.

JOURNAL OF PERSONALIZED MEDICINE (2022)

Editorial Material Peripheral Vascular Disease

Blood Pressure Variability in Patients With Acute Ischemic Stroke: Is It Worth Measuring?

Georgios Polychronopoulos, Dimitrios Milonas, Konstantinos Tziomalos

AMERICAN JOURNAL OF HYPERTENSION (2023)

Article Medicine, General & Internal

Hepatic Fibrosis Is a Risk Factor for Greater Severity and Worse Outcome of Acute Ischemic Stroke

Eleftheria Ztriva, Adonis Protopapas, Pavlos Mentizis, Anastasios Papadopoulos, Christiana Gogou, Maria Kiosi, Maria Kyziroglou, Ioanna Minopoulou, Anastasia Gkounta, Erofili Papathanasiou, Evangelos Cholongitas, Christos Savopoulos, Konstantinos Tziomalos

Summary: This study aimed to evaluate the relationship between hepatic fibrosis and the severity and outcome of acute ischemic stroke. The study found that hepatic fibrosis, assessed by the FIB-4 index, is associated with more severe ischemic stroke and may also be an independent risk factor for in-hospital mortality in patients admitted with acute ischemic stroke.

JOURNAL OF CLINICAL MEDICINE (2022)

Review Endocrinology & Metabolism

The Role of Novel Antibiotics in the Management of Diabetic Foot Infection

Efterpi Mougakou, Elpida Mastrogianni, Maria Kyziroglou, Konstantinos Tziomalos

Summary: Diabetic foot infection is a frequent and potentially life-threatening complication of diabetes mellitus. Antibiotic resistance has become a problem, leading to increasing rates of treatment failure. This review summarizes the safety and efficacy of novel antibiotics in treating diabetic foot infection, although more robust data and randomized controlled studies are needed. Cefiderocol and dalbavancin, which have been extensively studied in patients with bone infections, may be viable options for carefully selected patients with severe diabetic foot infection.

DIABETES THERAPY (2023)

Article Chemistry, Medicinal

Prevalence of Diabetes and Its Association with Atherosclerotic Cardiovascular Disease Risk in Patients with Familial Hypercholesterolemia: An Analysis from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH)

Chrysoula Boutari, Christos V. V. Rizos, Michalis Doumas, George Liamis, Ioannis Skoumas, Loukianos Rallidis, Anastasia Garoufi, Genovefa Kolovou, Konstantinos Tziomalos, Emmanouil Skalidis, Vasileios Kotsis, George Sfikas, Vaia Lambadiari, Panagiotis Anagnostis, Eleni Bilianou, Georgia Anastasiou, Iosif Koutagiar, Estela Kiouri, Achilleas Attilakos, Vana Kolovou, Evangelos Zacharis, Christina Antza, Evangelos Liberopoulos

Summary: Familial hypercholesterolemia (FH) and type 2 diabetes mellitus (T2DM) are both associated with a high risk of atherosclerotic cardiovascular disease (ASCVD). A study found that FH patients with T2DM had a higher prevalence of ASCVD, coronary artery disease (CAD), and stroke compared to those without T2DM. T2DM was significantly associated with prevalent ASCVD even after adjusting for various factors. FH patients with T2DM were also more likely to undergo coronary revascularization procedures. These findings highlight the importance of risk stratification and treatment intensity in FH patients.

PHARMACEUTICALS (2023)

Article Biochemistry & Molecular Biology

The Role of Histone Modifications in the Pathogenesis of Diabetic Kidney Disease

Christodoula Kourtidou, Konstantinos Tziomalos

Summary: Diabetic kidney disease (DKD) is the main cause of chronic kidney disease, with a multifactorial pathogenesis involving multiple molecular pathways. Recent studies have shown that histone modification plays a crucial role in the development and progression of DKD. Histone modification is believed to induce oxidative stress, inflammation, and fibrosis in the diabetic kidney. This review provides a summary of the current understanding of the association between histone modification and DKD.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Review Biochemistry & Molecular Biology

Microsomal Prostaglandin E Synthase-1 and-2: Emerging Targets in Non-Alcoholic Fatty Liver Disease

Dimitrios Kotsos, Konstantinos Tziomalos

Summary: Nonalcoholic fatty liver disease (NAFLD) is common in the general population and even more prevalent in obese and diabetic patients. NAFLD, especially nonalcoholic steatohepatitis (NASH), increases the risk for liver-related and cardiovascular morbidity. The development and progression of NAFLD involve complex and multifactorial pathogenesis, with potential involvement of microsomal prostaglandin E synthase-1 and -2. Targeting these enzymes may offer a novel therapeutic approach for NAFLD. This review discusses the association between microsomal prostaglandin E synthase-1 and -2 and NAFLD.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Biochemistry & Molecular Biology

Pharmacological Management of Obesity in Patients with Polycystic Ovary Syndrome

Christodoula Kourtidou, Konstantinos Tziomalos

Summary: Polycystic ovary syndrome (PCOS) is a common hormonal disorder in women of reproductive age, and excess body weight worsens its symptoms. Recent studies have evaluated various pharmacological agents for managing obesity in PCOS patients, with glucagon-like peptide-1 receptor agonists showing promising results in reducing body weight. Limited data suggest that sodium-glucose cotransporter-2 inhibitors and phosphodiesterase-4 inhibitors may also be effective. This review discusses the current evidence on the safety and efficacy of these agents in overweight and obese patients with PCOS.

BIOMEDICINES (2023)

Article Health Care Sciences & Services

Effects of Sodium-Glucose Co-Transporter-2 Inhibitors on Markers of Vascular Damage

Christodoula Kourtidou, Vasileios Rafailidis, Garyfallia Varouktsi, Efthimios Kanakis, Vassilios Liakopoulos, Timoleon-Achilleas Vyzantiadis, Christos Savopoulos, Smaragdi Marinaki, Maria Stangou, Konstantinos Tziomalos

Summary: SGLT2 inhibitors reduce arterial stiffness and have potential cardiovascular benefits for both high-risk and low-risk patients with type 2 diabetes mellitus.

JOURNAL OF PERSONALIZED MEDICINE (2023)

Article Medicine, Research & Experimental

The Role of Lipid-Lowering Treatment in the Secondary Prevention of Ischemic Stroke

Alexandra Tsankof, Konstantinos Tziomalos

Summary: Dyslipidemia is a major modifiable risk factor for ischemic stroke. Treatment with statins is important for secondary prevention of ischemic stroke. If LDL-C targets cannot be achieved with statins, ezetimibe can be added to the treatment. PCSK9 inhibitors can be considered for patients who do not reach LDL-C targets with statin/ezetimibe combination. Adding icosapent ethyl may reduce cardiovascular morbidity in patients with persistently elevated triglyceride levels despite achieving LDL-C targets.

DISEASES (2022)

No Data Available